Key Highlights

  • The offer comprises 932.8p in cash plus the 7.2p interim dividend, a 25.3% premium to the pre-offer-period close.
  • It values the fully diluted Share Capital at approximately £1,652m, roughly 10 times FY2025 adjusted EBITDA.
  • Specialist Technologies grew 16.7% organically at a 26.1% margin, on a 37% organic rise in aerospace and defence work.
  • The £80m buyback was suspended on 2 September after 2.57 million shares had been repurchased for £17.5m.

Bodycote plc (LSE:BOY), the Macclesfield-based heat treatment and thermal processing group, has become one of the London market's most contested Takeover situations of 2026. On 1 September 2026 its board unanimously backed a 940p-per-share cash offer from Vulcan Alpha Bidco, a vehicle for funds managed by US Private Equity firm Veritas Capital, valuing the FTSE 250 company at roughly £1.65bn. Within an hour, rival suitor CVC said it was "considering its position", leaving open the possibility of a counter-bid.

Three private equity houses have circled the company since May, and the key question for shareholders is whether 940p is the final word or merely the opening price in an auction for a Business whose aerospace and defence revenues are growing at double-digit rates.

Veritas wins board backing at 940p, but CVC has not walked away

The board-backed offer announced on 1 September 2026 comprises 932.8p in cash plus the 7.2p Interim Dividend declared with the half-year results, which shareholders keep in full. According to the announcement, the total of 940p represents a 25.3% premium to the closing price of 750.2p on 4 August 2026, the last business day before the Offer Period began, and a 37.5% premium to the three-month volume-weighted average price to 21 May 2026, the day before Bodycote first confirmed takeover interest.

The offer values Bodycote's fully diluted share capital at approximately £1,652m and implies an Enterprise value of around £1,852m, roughly 10 times FY2025 adjusted EBITDA of £184.7m.

The announcement describes an unusually crowded contest. Apollo Global Management made an unsolicited approach that Bodycote confirmed on 22 May 2026, before withdrawing under a Rule 2.8 statement on 5 June. Separate proposals from CVC and Veritas followed, and the offer period opened on 5 August 2026 when Bodycote disclosed two conditional proposals. Both bidders raised their terms several times: CVC reached 915p including the dividend and was granted Due Diligence access, while Veritas moved from 914p to a final 940p on 31 August, at which point the board judged it the only firm proposal on the table it could endorse.

Chair Daniel Dayan said the offer "reflects Bodycote's business quality and delivers shareholders excellent cash value". Veritas intends to retain the headquarters and operating footprint, support a buyout of the UK defined benefit pension scheme and avoid material headcount cuts beyond public-company functions, but also plans a twelve-month evaluation that will consider divesting parts of the automotive and industrial precision heat treatment business.

The deal is structured as a court-sanctioned scheme of arrangement, requiring 75% Shareholder approval by value plus competition and regulatory clearances, with completion expected in the first quarter of 2027. On 2 September the company suspended its £80m share buyback, under which it had repurchased 2.57 million shares for £17.5m since 11 March 2026.

What Bodycote does

Bodycote is the world's largest provider of outsourced heat treatment and thermal processing services, operating around 130 sites across 22 countries with an average of 4,127 employees in 2025. Manufacturers send it metal components, which it hardens, strengthens or protects using vacuum and atmospheric heat treatment, hot isostatic pressing (HIP) and the S3P surface-hardening process for stainless steel.

The group reports two core segments. Specialist Technologies, which includes HIP and S3P, serves aerospace, defence, space, medical, semiconductor and industrial gas turbine customers and earns the higher margins. Precision Heat Treatment is larger and more cyclical, tied to automotive and general industrial demand. In 2025, Western Europe generated £360.7m of Revenue and North America £276.2m, with emerging markets contributing £90.2m.

Half-year results: profit up 11% as aerospace and defence accelerate

Bodycote's interim results for the six months to 30 June 2026, published on 27 July 2026, showed revenue of £381.2m, up 3.3% on a reported basis and 6.5% organically, with core organic growth of 9.6%. Adjusted operating profit rose 10.7% to £61.0m, lifting the Margin by 110 basis points to 16.0%, while statutory operating profit also rose 10.7% to £45.6m. Statutory profit before tax was £41.2m and adjusted Basic Earnings Per Share climbed 18.3% to 25.2p.

Specialist Technologies grew 16.7% organically to £121.2m at a 26.1% margin, driven by a 37% organic increase in aerospace and defence work. Precision Heat Treatment grew 6.4% organically to £250.8m at a 15.0% margin, although automotive revenue fell 4% on continued Western European weakness. Free Cash Flow slipped 19.4% to £14.5m as Capital Investment continued, and net Debt excluding leases stood at £135.2m, or 0.7 times EBITDA. The interim dividend was raised 4.3% to 7.2p.

For context, full-year 2025 revenue was £727.1m, down 4.0%, with adjusted operating profit of £114.3m at a 15.7% margin and a maintained 23.0p dividend. The Optimise programme, which is closing or consolidating 31 sub-scale sites, had completed 27 by June 2026 and targets run-rate benefits of at least £15m by mid-2027.

What could move the shares next

The most immediate catalyst is CVC. Its 1 September statement was a Rule 2.4 possible-offer announcement rather than a firm bid, but CVC has completed due diligence and had already proposed 915p. Any improved proposal above 940p would test whether Veritas is willing to raise again. The Veritas scheme document, due within 28 days of the offer announcement, will also fix the shareholder meeting dates.

Beyond the bid, management expects core organic revenue growth for 2026, led by aerospace, defence and industrial gas turbines, where data-centre power Demand is supporting orders. New greenfield plants in South Korea and Mexico are due to open in 2027, and further Optimise benefits should support margins.

Risks investors should watch

The obvious risk is deal completion. The offer needs 75% shareholder approval by value and competition clearances across multiple jurisdictions. If both bidders were to withdraw, the shares could return towards the 750p level seen before the offer period, with the buyback on hold in the meantime.

Operationally, Western European automotive remains structurally weak, oil and gas revenue fell 2% in the first half, and management has warned that second-half growth will moderate against tougher comparators, with higher variable pay and growth-project ramp-up costs weighing on margins. Free cash flow has fallen in the last two reporting periods as capex rises.

Outlook

For now, the Bodycote (LSE:BOY) share price is being set by a takeover process rather than by its trading. The board has endorsed 940p from Veritas, but CVC's decision to keep its Options open means the contest is not yet settled. Investors should watch for a firm response from CVC, publication of the scheme document, the court and general meeting timetable, and regulatory clearances.

Whatever the outcome, the half-year numbers show a business whose higher-margin Specialist Technologies arm is compounding on aerospace and defence demand while restructuring lifts group margins. That explains why three private equity bidders have pursued it, and why its 2026 story is far from over.